Märten A - Search Results

1

Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).

Popat S, Hsia TC, Hung JY, Jung HA, Shih JY, Park CK, Lee SH, Okamoto T, Ahn HK, Lee YC, Sato Y, Lee SS, Mascaux C, Daoud H, Märten A, Miura S. Popat S, et al. Among authors: marten a. Oncologist. 2022 Apr 5;27(4):255-265. doi: 10.1093/oncolo/oyac022. Oncologist. 2022. PMID: 35274704 Free PMC article.

2

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.

Yang JC, Schuler M, Popat S, Miura S, Heeke S, Park K, Märten A, Kim ES. Yang JC, et al. Among authors: marten a. J Thorac Oncol. 2020 May;15(5):803-815. doi: 10.1016/j.jtho.2019.12.126. Epub 2020 Jan 10. J Thorac Oncol. 2020. PMID: 31931137 Free article. Clinical Trial.

3

Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).

Popat S, Jung HA, Lee SY, Hochmair MJ, Lee SH, Escriu C, Lee MK, Migliorino MR, Lee YC, Girard N, Daoud H, Märten A, Miura S. Popat S, et al. Among authors: marten a. Lung Cancer. 2021 Dec;162:9-15. doi: 10.1016/j.lungcan.2021.09.009. Epub 2021 Sep 21. Lung Cancer. 2021. PMID: 34649106 Free article.

4

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.

Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, Griesinger F, Scheffler M; Afatinib Compassionate Use Consortium (ACUC). Heigener DF, et al. Among authors: marten a. Oncologist. 2015 Oct;20(10):1167-74. doi: 10.1634/theoncologist.2015-0073. Epub 2015 Sep 9. Oncologist. 2015. PMID: 26354527 Free PMC article.

5

Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).

Halmos B, Tan EH, Soo RA, Cadranel J, Lee MK, Foucher P, Hsia TC, Hochmair M, Griesinger F, Hida T, Kim E, Melosky B, Märten A, Carcereny E. Halmos B, et al. Among authors: marten a. Lung Cancer. 2019 Jan;127:103-111. doi: 10.1016/j.lungcan.2018.10.028. Epub 2018 Nov 2. Lung Cancer. 2019. PMID: 30642537 Free article.

6

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report.

Yang JC, Schuler M, Popat S, Miura S, Park K, Passaro A, De Marinis F, Solca F, Märten A, Kim ES. Yang JC, et al. Among authors: marten a. Front Oncol. 2022 Apr 28;12:834704. doi: 10.3389/fonc.2022.834704. eCollection 2022. Front Oncol. 2022. PMID: 35574304 Free PMC article.

7

Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies.

Miura S, Jung HA, Lee SY, Lee SH, Lee MK, Lee YC, Hochmair MJ, Yang CT, Märten A, Yang JC, Popat S. Miura S, et al. Among authors: marten a. Onco Targets Ther. 2022 Aug 22;15:873-882. doi: 10.2147/OTT.S362535. eCollection 2022. Onco Targets Ther. 2022. PMID: 36033903 Free PMC article.

8

Treatments for EGFR Mutation-Positive (M+) NSCLC Patients - A Network Meta-Analysis (NMA) by Mutation Type.

Popat S, Lungershausen J, Griebsch I, Marten A, Wu YL. Popat S, et al. Among authors: marten a. Value Health. 2014 Nov;17(7):A615. doi: 10.1016/j.jval.2014.08.2166. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202154 Free article. No abstract available.

9

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.

Park K, Kim JS, Kim JH, Kim YC, Kim HG, Cho EK, Jin JY, Kim M, Märten A, Kang JH. Park K, et al. Among authors: marten a. BMC Cancer. 2021 Jul 12;21(1):802. doi: 10.1186/s12885-021-08445-9. BMC Cancer. 2021. PMID: 34253172 Free PMC article.

10

Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.

Schuler M, Fischer JR, Grohé C, Gütz S, Thomas M, Kimmich M, Schneider CP, Laack E, Märten A; Afatinib Compassionate Use Consortium. Schuler M, et al. Among authors: marten a. Oncologist. 2014 Oct;19(10):1100-9. doi: 10.1634/theoncologist.2014-0103. Epub 2014 Sep 17. Oncologist. 2014. PMID: 25232040 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

140 results

Search Page

Filters